SAN DIEGO, Dec. 21, 2021 (GLOBE NEWSWIRE) — Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, announced today the closing of its previously announced private placement for the issuance and sale of 8,235,297 shares of common stock and warrants to purchase up to an aggregate of 8,235,297 shares of common stock, at a purchase price of $0.425 per share of common stock and associated warrant. The warrants have an exercise price of $0.425 per share of common stock and are exercisable commencing six months and one day following the date of issuance for a period of five and one-half years from the date of issuance.
News
Histogen to Report Third Quarter 2021 Financial Results on November 10, 2021
SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) — Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that Histogen’s financial results for the third quarter will be released after… Click here to view original post… […]
News
Histogen Announces $3.5 Million Private Placement
SAN DIEGO, Dec. 16, 2021 (GLOBE NEWSWIRE) — Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, announced today that it has entered into securities purchase agreements with certain institutional and… Click here to view original post… […]
News
Histogen to Present at the Canaccord Genuity 41st Annual Growth Conference
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) — Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that Richard W. Pascoe, President and Chief Executive Officer of Histogen,… Click here to view original post… […]
